11:57:49 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Bokslutskommuniké 2024
2024-05-03 Kvartalsrapport 2024-Q3
2024-04-12 Extra Bolagsstämma 2024
2024-02-09 Kvartalsrapport 2024-Q2
2023-10-27 Kvartalsrapport 2024-Q1
2023-09-25 Ordinarie utdelning VSD B 0.00 SEK
2023-09-22 Årsstämma 2024
2023-08-31 Bokslutskommuniké 2023
2023-05-04 Kvartalsrapport 2023-Q3
2023-02-09 Kvartalsrapport 2023-Q2
2022-10-27 Kvartalsrapport 2023-Q1
2022-10-07 Ordinarie utdelning VSD B 0.00 SEK
2022-10-06 Årsstämma 2023
2022-08-30 Bokslutskommuniké 2022
2022-07-05 Extra Bolagsstämma 2022
2022-05-04 Kvartalsrapport 2022-Q3
2022-02-11 Kvartalsrapport 2022-Q2
2021-10-22 Kvartalsrapport 2022-Q1
2021-10-06 Ordinarie utdelning VSD B 0.00 SEK
2021-10-05 Årsstämma 2022
2021-08-30 Bokslutskommuniké 2021
2021-05-12 Kvartalsrapport 2021-Q3
2021-02-12 Kvartalsrapport 2021-Q2
2020-11-12 Kvartalsrapport 2021-Q1
2020-10-08 Ordinarie utdelning VSD B 0.00 SEK
2020-10-07 Årsstämma 2021
2020-08-31 Bokslutskommuniké 2020
2020-05-15 Kvartalsrapport 2020-Q3
2020-05-04 Extra Bolagsstämma 2020
2020-02-14 Kvartalsrapport 2020-Q2
2019-11-01 Kvartalsrapport 2020-Q1
2019-10-10 Ordinarie utdelning VSD B 0.00 SEK
2019-10-09 Årsstämma 2020
2019-08-30 Bokslutskommuniké 2019
2019-05-16 Kvartalsrapport 2019-Q3
2019-02-14 Kvartalsrapport 2019-Q2
2018-10-30 Kvartalsrapport 2019-Q1
2018-10-17 Ordinarie utdelning VSD B 0.00 SEK
2018-10-16 Årsstämma 2019
2018-08-31 Bokslutskommuniké 2018
2018-05-16 Kvartalsrapport 2018-Q3
2018-02-14 Kvartalsrapport 2018-Q2
2017-10-30 Kvartalsrapport 2018-Q1
2017-10-02 Ordinarie utdelning VSD B 0.00 SEK
2017-09-29 Årsstämma 2018
2017-08-30 Bokslutskommuniké 2017
2017-05-22 Kvartalsrapport 2017-Q3
2017-02-20 Kvartalsrapport 2017-Q2
2017-01-25 Extra Bolagsstämma 2017
2016-11-07 Kvartalsrapport 2017-Q1
2016-08-29 Ordinarie utdelning VSD B 0.00 SEK
2016-08-26 Bokslutskommuniké 2016
2016-05-26 Kvartalsrapport 2016-Q3
2016-02-25 Kvartalsrapport 2016-Q2
2015-11-26 Kvartalsrapport 2016-Q1
2015-08-27 Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Vibrosense Dynamics är verksamt inom medicinteknik. Bolaget utvecklar produkter och tjänster för diagnostikstöd vid nervskador i händer och fötter. Produkterna mäter och kvantifierar förmågan att känna vibrationer i huden, och används av vårdgivare för att kunna anpassa behandlingen eller sätta in förebyggande åtgärder vid potentiella nervskador. Bolagets kunder består huvudsakligen av diabetesmottagningar, sjukhus, vårdcentraler och forskningsinstitut.
2022-02-17 10:35:00

VibroSense Dynamics AB (VibroSense) has today signed an exclusive distributor agreement with the Chinese state-owned company Genertec Universal Medical Group (UMCARE).

The distributor agreement means that UMCARE receives the exclusive right to sell VibroSense's product VibroSense Meter® II, targeting screening of diabetic feet, in the Chinese market. The agreement also includes agreements of extensive marketing and sales execution by UMCARE in the Chinese market.

UMCARE will also be responsible for the execution and submission of a regulatory market approval in China, which is defined in a separate agreement signed between the parties in December 2021. Sales with deliveries will start when VibroSense Meter® II has received regulatory market approval in China, which is estimated to be finalized during Q2 2023.

"I am very proud and pleased that we now can start the process of launching our instrument VibroSense Meter II and the application Diabetes Foot Screening in China. At the same time, I am impressed by UMCARE, who has acted both humbly and very professionally throughout the entire negotiation process. The collaboration with UMCARE provides us with an entirely new platform to work from and opens up new interesting opportunities for the future. I look forward with great confidence to our new partnership and I am very hopeful as we now enter a new phase where we can plan for the launch of Diabetes Foot Screening in China, which is the world's single largest market in diabetes care", says Hans Wallin, CEO at VibroSense Dynamics.

 "We look forward to collaborate with VibroSense to launch and sell VibroSense Meter II to the diabetes care sector in China. UMCARE has a well-developed organization with its own hospitals and a very good infrastructure for marketing, sales and distribution in the Chinese healthcare sector. Our broad network of contacts in the segments we work in will strengthen our position when we start launching VibroSense Meter II in China", says Mr. Chongyang Huang, Director of Medical Equipment Business, at the Genertec Universal Medical Group.

About diabetes in China
According to an estimate from the American Diabetes Association (ADA) from 2020, there are about 130 million patients with diabetes in China, making China the largest market for diabetes care in the world. There are about 36,000 hospitals in China, of which 24,000 are private and 12,000 are public. The cost of diabetes care in China is estimated at the equivalent of SEK 800 billion per year

Contact
Hans Wallin, CEO VibroSense Dynamics AB,
Phone: +46 40 88 026
E-mail: info@vibrosense.com
www.vibrosense.com

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (public) sells and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. Our vision is that the VibroSense Meter® shall be the golden standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.